Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q3 FY2021 Earnings Presentation
18 slides from Advanced Enzyme Technologies's earnings presentation, Feb 12, 2021
Slide 1: Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited Earnings Presentation | Q3FY21
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to Advanced Enzymes is a research driven com
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Manufacturing Units – 7 R&D Units – 6 } India – 4 | USA – 1 | Germany –1 India – 5 I USA - 2 REVENUE (₹ mn) 1st 2nd 2nd 4,440 Indian enzyme company Highest market share in Listed integrated 2,938 India enzyme player globally FY 16 FY 20 EBI
Slide 5: Results Summary – Q3FY21 (Consolidated) Y-o-Y
Results Summary – Q3FY21 (Consolidated) Y-o-Y *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,377 664 1,119 529 443 346 Q3FY20 Q3FY21 Q3FY20 Q3FY21 Q3FY20 Q3FY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing 30% -24% Q3FY21 105 Q3FY21 1,089 Q3FY21 183 (1%) Q3FY20 Q3FY2
Slide 6: Revenue Split – Q3FY21 vs. Q3FY20
Revenue Split – Q3FY21 vs. Q3FY20 Q3FY21 Q3FY20 Product Category-wise (%) Product Category-wise (%) 13% 8% 15% 13% 79% 72% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 3% 2% 5% 39% 42% 52% 43% 6% 7% Asia (ex- Ind
Slide 7: Results Summary – 9MFY21 (Consolidated) Y-o-Y
Results Summary – 9MFY21 (Consolidated) Y-o-Y *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 3,686 1,766 3,337 1,536 1,177 1,004 9MFY20 9MFY21 9MFY20 9MFY21 9MFY20 9MFY21 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing 16% -24% 9MFY21 344 9MFY21 2,861 1% 9MFY21 (1%) 481 9
Slide 8: Revenue Split – 9MFY21 vs. 9MFY20
Revenue Split – 9MFY21 vs. 9MFY20 9MFY21 9MFY20 Product Category-wise (%) Product Category-wise (%) 13% 9% 15% 12% 78% 73% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 4% 5% 42% 44% 47% 42% 5% 7% Asia (ex- Ind
Slide 9: Profit & Loss (Consolidated) – Q3FY21 & 9MFY21
Profit & Loss (Consolidated) – Q2FY21 & 9MFY21 ₹ in Million except per share data Q3FY21 Q2FY21 Q3FY20 Y-o-Y 9MFY21 9MFY20 Particulars Y-o-Y (%) Unaudited Unaudited Unaudited (%) Unaudited Unaudited Income from Operations 1,377 1,204 1,119 23% 3,686 3,337 10% Expenses 778 687 654 19% 2,120 1,992 6%
Slide 10: Balance Sheet (Consolidated) – 9MFY21
Balance Sheet (Consolidated) – 9MFY21 ₹ in Million 9MFY21 9MFY20 Particulars Unaudited Audited Assets Property, plant and equipment 1,993 2,021 Capital work-in-progress 143 176 Intangible assets 575 591 Goodwill 2,884 2,792 Other non-current assets 193 184 Current assets 4,833 3,484 Assets held for
Slide 11: Results Summary – FY20
Results Summary – FY20 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,440 2,023 4,196 1,819 1,330 1,159 FY19 FY20 FY19 FY20 FY19 FY20 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% FY20 3,211 ( FY20 555 FY20 536 FY19 493 FY19 3,133 FY19 512 9% 2% 8% Note: 1. On Co
Slide 12: Revenue Split – FY20
Revenue Split – FY20 FY20 FY19 Product Category-wise (%) Product Category-wise (%) 13% 12% 12% 12% 75% 76% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 2% 6% 4% 42% 49% 40% 43% 7% 5% Asia (ex- India) Others India
Slide 13: Profit & Loss (Consolidated) – FY20
Profit & Loss (Consolidated) – FY20 ₹ in Million except per share data FY20 FY19 Particulars Y-o-Y (%) Audited Audited Income from Operations 4,440 4,196 6% Expenses 2,675 2,587 3% Profit from Operations before Other Income, Finance Costs and 1,765 1,609 10% Exceptional Item Other Income 57 50 12% P
Slide 14: Balance Sheet (Consolidated) – FY20
Balance Sheet (Consolidated) – FY20 ₹ in Million FY20 FY19 Particulars Audited Audited Assets Property, plant and equipment 2,042 1,618 Capital work-in-progress 101 105 Intangible assets 646 622 Goodwill 2,941 2,715 Other non-current assets 195 183 Current assets 3,813 2,820 Assets held for sale 48
Slide 15: Strong Financial Performance – FY20
Strong Financial Performance – FY20 ₹ in Million Revenue from Operations EBIDTA & EBIDTA Margin (%) 4,440 2,500 47% 43% 46% 50% 3,957 4,196 2,000 42% 48% 3,431 45% 46% 2,938 1,500 1,654 44% 1,534 2,023 1,000 1,389 42% 1,819 40% 500 38% 0 36% FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 FY 2
Slide 16: Strong Financial Performance – FY20
Strong Financial Performance – FY20 Net Working Capital (Days) Net Worth (₹ mn) 8,396 119 6,788 115 5,591 112 4,640 108 105 2,781 FY 16 FY 17 FY 18 FY 19 FY 20 FY 16 FY 17 FY 18 FY 19 FY 20 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.4 27% 27% 24% 21% 28% 19% 18% 19% 0.1 16% 0.01 0.02 0.00 FY 16
Slide 17: Shareholder Information
Shareholder Information Top 5 Institutional Holders (As on 05th February 2021) Stock Data (As on 11th February 2021) Institutions OS (%) ORBIMED ASIA III MAURITIUS 12.09 Market Capitalization (₹) 41,623 mn HDFC AMC 5.63 Shares Outstanding 111.72 mn NALANDA INDIA EQUITY FUND 4.75 Free Float 4.55 mn O
Slide 18: Thank You
Thank You Advanced Enzyme Technologies Limited Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Web: www.advancedenzymes.com Fax: + 91-22-25835159
Advanced Enzyme Technologies — Q3 FY2021 Earnings Presentation on 6ix